title: Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
abstract: OBJECTIVE
  Malignant mesothelioma has a poor prognosis and is refractory to many agents. The antitumor effectiveness of cisplatin, paclitaxel, and suramin as single agents and in combination was evaluated in vivo against four lines of human pleural malignant mesothelioma xenografts in athymic nude mice, including one epithelial type and three fibrosarcomatous.
  
  
  METHODS
  After growth of tumors occurred by day 54 or 55, mice were randomized in groups of four each to receive either cisplatin 4 mg/kg intraperitoneally weekly x5, or paclitaxel (Taxol) 12.5 mg/kg subcutaneously daily 5 days/week for 3 consecutive weeks, or suramin 60 mg/kg intraperitoneally daily x4,versus controls treated with normal saline.
  
  
  RESULTS
  Cisplatin was very effective against one line and also to a lesser degree against another line. Paclitaxel showed antitumor effects similar to cisplatin, being very effective in one line, and also showed good activity in another line. Suramin was basically inactive in all four lines. Following the results obtained with these single agents, it was decided to evaluate the combination of cisplatin and paclitaxel, which resulted in more pronounced antitumor effect in all four cell lines.
  
  
  CONCLUSIONS
  These results indicate that the combination of cisplatin and paclitaxel is superior to each agent alone in this model, and that it deserves to be evaluated in patients with malignant mesothelioma.
authors.affiliation: Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Chahinian
authors.forename: J P
authors.initials: JP
authors.lastname: Mandeli
authors.forename: H
authors.initials: H
authors.lastname: Gluck
authors.forename: H
authors.initials: H
authors.lastname: Naim
authors.forename: A S
authors.initials: AS
authors.lastname: Teirstein
authors.forename: J F
authors.initials: JF
authors.lastname: Holland
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005354:Fibrosarcoma / Q000473:pathology; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D017239:Paclitaxel / Q000008:administration & dosage; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012509:Sarcoma / Q000473:pathology; D013498:Suramin / Q000008:administration & dosage; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D013498:Suramin; D017239:Paclitaxel; D002945:Cisplatin